Table 5.

GRADE Summary of Findings reporting the comparative efficacy of different pharmacological agents for inducing clinical remission in biologic-naïve patients with moderate to severe luminal Crohn’s disease based on network meta-analysis

Medications	Relative effect (Odds ratio, 95% CI)	Overall Quality of Evidence
Selected agents vs. Infliximab
Adalimumab	0.64 (0.22–1.88)	Low (very serious imprecision)
Certolizumab pegol	0.23 (0.10–0.55)	Moderate (imprecision)
Vedolizumab	0.46 (0.16–1.26)	Low (very serious imprecision)
Ustekinumab	0.47 (0.19–1.12)	Low (very serious imprecision)
Selected agents vs. Adalimumab
Certolizumab pegol	0.36 (0.15–0.86)	Moderate (imprecision)
Vedolizumab	0.71 (0.25–1.98)	Low (very serious imprecision)
Ustekinumab	0.73 (0.30–1.76)	Low (very serious imprecision)
Selected agents vs. Certolizumab pegol
Vedolizumab	1.97 (0.88–4.41)	Low (very serious imprecision)
Ustekinumab	2.02 (1.09–3.75)	Moderate (imprecision)
Selected agents vs. Vedolizumab
Ustekinumab	1.02 (0.45–2.32)	Low (very serious imprecision)

^*Even though trials of infliximab used non-conventional infliximab doses or dosing regimens (one trial only used single dose, another trial treated all patients concomitantly with thiopurines), we opted not to rate down for intransitivity since effect estimates using conventional dosing regimens were likely to be more favorable